Neuroscientific Biopharmaceuticals (ASX:NSB) — Material Events
ASX:NSB · 9 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
NeuroScientific’s StemSmart™ Shows Promise in Tough Crohn’s CasesMedium
NeuroScientific reports positive clinical responses in Crohn's disease patients treated with StemSmart™ under Special Access Program
13 Jan 2026
·ASX Announcement
·85
NeuroScientific Advances StemSmart Clinical Program and Manufacturing Scale-UpMedium
NeuroScientific reports positive StemSmart clinical results, advances manufacturing and Phase 2 trial plans
30 Apr 2026
·Quarterly Activities Report
·85
NeuroScientific Advances StemSmart™ Trials with New Leadership and Manufacturing Scale-UpMedium
NeuroScientific advances StemSmart™ clinical program and leadership; $6.9M cash at Q1 FY26
30 Oct 2025
·Quarterly Activity Report
·80
NeuroScientific Reports $4.69M Loss, Advances StemSmart Clinical Program, Ceases EmtinB DevelopmentMedium
NeuroScientific reports $4.69M loss, advances StemSmart clinical program, ceases EmtinB development
25 Aug 2026
·Annual Report and Financial Results
·75
NeuroScientific Advances StemSmart™ Therapy with Fourth Patient TreatmentMedium
NeuroScientific Treats Fourth Patient Under Special Access Scheme, Progressing StemSmart™ Phase 2 Trial
11 Nov 2025
·ASX Announcement
·75
NeuroScientific Reports Early Success in StemSmart™ Crohn’s Treatment ProgramMedium
NeuroScientific advances StemSmart™ clinical program with positive patient responses and strong cash position
30 Jan 2026
·Quarterly Activity Report
·75
NSB Secures FDA Pre-IND Meeting for StemSmart Phase 2 Trial in Refractory Crohn’sMedium
NSB schedules Pre-IND meeting with US FDA for Phase 2 trial of StemSmart in refractory Crohn's disease
13 Aug 2026
·Regulatory Update
·75
NeuroScientific Reports 80% Clinical Response in Crohn’s Disease Patients with StemSmartMedium
NeuroScientific reports positive clinical results for StemSmart™ in Crohn's disease and advances Phase 2 trial planning
28 July 2026
·Quarterly Activities Report
·75
No articles in this tier for the last 12 months.
Market Mentions
6
- appeared in market wrap coverage
These are market wrap articles where Neuroscientific Biopharmaceuticals (ASX:NSB) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026
29 Aug 2026
Healthcare Wrap - Week 33 (10 Aug -> 14 Aug) 2026
15 Aug 2026
Healthcare Wrap - Week 31 (27 July -> 31 July) 2026
1 Aug 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026